Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Risk stratification syndromes

Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Circulation 2002 105 1760-1763. [Pg.472]

Heeschen C, Hamm CW, MhrovicV etal. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004 ... [Pg.472]

Birnbaum Y, Atar S. Electrocardiogram risk stratification of non ST elevation acute coronary syndrome. J Electrocardiol 2006 39 558. [Pg.311]

Collinson J, Flather MO, Fox KA et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000 21 1450. [Pg.313]

Westerhout CM, Fu Y, Lauer MS et al. Short- and long-term risk stratification in acute coronary syndromes the added value of quantitative ST-segment depression and multiple biomarkers. J Am Coll Cardiol 2006 48 939. [Pg.323]

Pepine CJ. An ischemia-gmded approach for risk stratification in patients with acute coronary syndromes. Am J Cardiol 2000 86 27M-35M. [Pg.288]

FIGURE 2.1 Algorithm for risk stratification and treatment of patients with acute coronary syndromes. (STEMI, ST-elevation myocardial infarction NSTEMI, non-STEMI.)... [Pg.22]

Table 2.1 American College of Cardiology/American Heart Association system for risk stratification of patients with non-ST-elevation acute coronary syndromes... [Pg.23]

Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Circulation 2002 105(15)4760-3. Ikonomidis I, Lekakis J, Revela I, et al. Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J 2005 26(16)4618-24. [Pg.80]

Serum biomarkers of acute coronary syndrome play a critical role in the diagnosis and risk stratification of patients with ACS. Myocardial necrosis observed in patients with ACS releases a variety of proteins into blood that can be used as biomarkers. Antiquated markers include aspartate aminotransferase, lactate dehydrogenase (LD) and its isoenzyme (LDl), myoglobin, and creatine kinase (CK) and its isoenzyme (CK-MB). While some of these markers are still in routine use, there is consensus among experts in the field of cardiology, emergency medicine, and laboratory medicine that cardiac troponin is the gold standard marker for ACS. [Pg.1807]

See other pages where Risk stratification syndromes is mentioned: [Pg.465]    [Pg.191]    [Pg.341]    [Pg.341]    [Pg.991]    [Pg.286]    [Pg.15]    [Pg.36]    [Pg.67]    [Pg.94]   
See also in sourсe #XX -- [ Pg.22 , Pg.24 ]



SEARCH



Acute coronary syndromes risk stratification

Risk stratification

Stratification

© 2024 chempedia.info